Evidence map›Paper›PMID 36842486›Full record

Trial reportAmerican heart journal2023

The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial.

Jenica N Upshaw, Susan Parker, Douglas Gregory, Benjamin Koethe, Amanda R Vest, Ayan R Patel, Michael S Kiernan, David DeNofrio, Eric Davidson, Sharanya Mohanty and 9 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in American heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jenica N UpshawThe CardioVascular Center, Tufts Medical Center, Boston, MA. Electronic address: jupshaw@tuftsmedicalcenter.org.
Susan ParkerNew England Quality Care Alliance, Braintree, MA.
Douglas GregoryCardiovascular Clinical Studies, Boston MA.
Benjamin KoetheBiostatics, Epidemiology, and Research Design Center, Tufts Medical Center, Boston MA.
Amanda R VestThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Ayan R PatelThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Michael S KiernanThe CardioVascular Center, Tufts Medical Center, Boston, MA.
David DeNofrioThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Eric DavidsonHeart Center of Metrowest, Framingham MA.
Sharanya MohantyThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Patrick ArpinThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Nicole StraussThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Crystal SommerThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Linda BrandonNew England Quality Care Alliance, Braintree, MA.
Rita ButlerThe CardioVascular Center, Tufts Medical Center, Boston, MA.
Henry DwaahTufts University School of Medicine, Boston, MA.
Hilary NadeauNew England Quality Care Alliance, Braintree, MA.
Michael CantorNew England Quality Care Alliance, Braintree, MA.
Marvin A KonstamThe CardioVascular Center, Tufts Medical Center, Boston, MA.

Funding

CTSA Graduate ProgramTL1TR002546 · NCATS · TUFTS UNIVERSITY BOSTON · PI KENT, DAVID M · 2018 to 2022
$4.2M
Prevention of Anthracycline Chemotherapy CardiotoxicityK08HL146959 · NHLBI · TUFTS MEDICAL CENTER · PI UPSHAW, JENICA · 2020 to 2024
$885k
NCATS NIH HHS TL1 TR002546NHLBI NIH HHS K08 HL146959
6 · The paper itself

Abstract

backgroundMobile health applications are becoming increasingly common. Prior work has demonstrated reduced heart failure (HF) hospitalizations with HF disease management programs; however, few of these programs have used tablet computer-based technology.

methodsParticipants with a diagnosis of HF and at least 1 high risk feature for hospitalization were randomized to either an established telephone-based disease management program or the same disease management program with the addition of remote monitoring of weight, blood pressure, heart rate and symptoms via a tablet computer for 90 days. The primary endpoint was the number of days hospitalized for HF assessed at 90 days.

resultsFrom August 2014 to April 2019, 212 participants from 3 hospitals in Massachusetts were randomized 3:1 to telemonitoring-based HF disease management (n = 159) or telephone-based HF disease management (n = 53) with 98% of individuals in both study groups completing the 90 days of follow-up. There was no significant difference in the number of days hospitalized for HF between the telemonitoring disease management group (0.88 ± 3.28 days per patient-90 days) and the telephone-based disease management group (1.00 ± 2.97 days per patient-90 days); incidence rate ratio 0.82 (95% confidence interval, 0.43-1.58; P = .442).

conclusionsThe addition of tablet-based telemonitoring to an established HF telephone-based disease management program did not reduce HF hospitalizations; however, study power was limited.

Indexed as

Heart FailureTelemedicineComputers, HandheldDisease ManagementHospitalizationHumansTelephone

Identifiers

PMID36842486
PMCPMC11195537

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.